3Gahr M, Kolle MA, Schonfeldt-Leeuona C, et al. Paliperidone extended-release: does it have a place in antipsychot c therapy? [J]. Drug Des Devel Ther, 2011, 5 (11): 125 146.
4Leucht S, IZorves IZ, Arbter D, et al. Second-generation versus firstLgeneration antipsychotic drugs for schizophrenia= a meta a- nalysis [J]. Lancet, 2009, 373 (9657).. 31-41.
5Jaquenoud SE, Knezevic B, Morena GP, et al. ABCB1 and cy- tochrome P450 polymorphisms: clinical pharmacogenetics of clozapine [J]. J Clin Psychopharmacol, 2009, 29 (4) : 319-326.
6Prior TI, Chue PS, Tibbo P, et al. Drug metabolism and atyp ical antipsychotics [J]. Eur Neuropsyehopharmaeol, 1999, 9 (4) 301 309.
7Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical antipsychotics= involvement of cytochrome p450 enzymes and relevance :[or drugdrug interactions[J]. Curr Drug Metab, 2008, 9 (5): 410-418.
8Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics.- considerations for clinicians and patients [J]. Psychopharmacol Bull, 2007, 40 (1) = 77-97.
9Chetty M, Murray M. CYP mediated clozapine interactions: how predictable are they? [J]. Curr Drug Metab, 2007, 8 (4): 307-313.
10Chetty M, l)Esposito F , Zhang WV, et al. In vitro and in vi vo evaluation of the inhibition potential of risperidone toward clozapine biotransformation [J]. Br J Clin Pharmacol, 2009, 68(4) 574-579.
